Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
Level 5 - mechanism / opinion, no new human data
Expert consensus clinical practice guideline and care pathway without primary human trial data
PubMed 34602251 · doi:10.1053/j.gastro.2021.07.049
What was done
The American Gastroenterological Association convened a multidisciplinary expert panel to develop a Clinical Care Pathway providing explicit guidance on screening, diagnosing, risk stratifying, and treating nonalcoholic fatty liver disease (NAFLD), focusing on identifying clinically significant fibrosis (stages F2–F4) across primary care, endocrinology, obesity medicine, and gastroenterology settings.
What was found
The abstract reports that NAFLD affects approximately 37% of US adults and is largely asymptomatic. No empirical study data, diagnostic accuracy values, or treatment effect sizes are reported in the abstract.
Why it matters
This care pathway provides a standardized, multidisciplinary framework to help front-line and specialty clinicians identify high-risk fibrosis early and coordinate appropriate management.
Limits
The publication is an expert consensus guideline and narrative pathway rather than an empirical trial or systematic review. The abstract reports no quantitative implementation outcomes, diagnostic performance metrics, or clinical trial data.
Cited by
- contradicts Non-alcoholic fatty liver disease affects 45% of American adults.